Dianthus Therapeutics, Inc. (DNTH) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -7973.3%, revenue growth 2950.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $2.04M |
| Revenue (TTM) | $0.0B |
| Net Margin | -7973.3% |
| Operating Margin (TTM) | -1875.5% |
| Revenue Growth (YoY) | 2950.8% |
| EPS Growth (YoY) | 2.3% |
| Price / Book | 5.08 |
| Price / Sales | 512.44 |
| Altman Z-Score | 74.72 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
DNTH overview · DNTH earnings · DNTH KPIs · DNTH documents · DNTH ownership · DNTH peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.